Ico Badalona - Hospital Universitari Germans Trias I Pujol

Badalona 8916

2 studies enrolling now · 6 studies all time

What they study most

Advanced Breast Cancer, Breast Cancer, Diffuse Large B-Cell Lymphoma, Diffuse Large B-cell Lymphoma, Gastric Cancer, Gastroesophageal Junction Cancer, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Leukemia, Metastatic Breast Cancer, Myelofibrosis, PIK3CA Mutation

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Running, not enrolling
• Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma — Stopped early
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML — Running, not enrolling
• A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) — Running, not enrolling